4.6 Article

Cytoplasmic Utilization of Human Immunodeficiency Virus Type 1 Genomic RNA Is Not Dependent on a Nuclear Interaction with Gag

Journal

JOURNAL OF VIROLOGY
Volume 86, Issue 6, Pages 2990-3002

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.06874-11

Keywords

-

Categories

Funding

  1. DFG [Ue45/11-1, 1045/2]

Ask authors/readers for more resources

In some retroviruses, such as Rous sarcoma virus and prototype foamy virus, Gag proteins are known to shuttle between the nucleus and the cytoplasm and are implicated in nuclear export of the viral genomic unspliced RNA (gRNA) for subsequent encapsidation. A similar function has been proposed for human immunodeficiency virus type 1 (HIV-1) Gag based on the identification of nuclear localization and export signals. However, the ability of HIV-1 Gag to transit through the nucleus has never been confirmed. In addition, the lentiviral Rev protein promotes efficient nuclear gRNA export, and previous reports indicate a cytoplasmic interaction between Gag and gRNA. Therefore, functional effects of HIV-1 Gag on gRNA and its usage were explored. Expression of gag in the absence of Rev was not able to increase cytoplasmic gRNA levels of subgenomic, proviral, or lentiviral vector constructs, and gene expression from genomic reporter plasmids could not be induced by Gag provided in trans. Furthermore, Gag lacking the reported nuclear localization and export signals was still able to mediate an efficient packaging process. Although small amounts of Gag were detectable in the nuclei of transfected cells, a Crm1-dependent nuclear export signal in Gag could not be confirmed. Thus, our study does not provide any evidence for a nuclear function of HIV-1 Gag. The encapsidation process of HIV-1 therefore clearly differs from that of Rous sarcoma virus and prototype foamy virus.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Immunology

Comparative analysis of clinics, pathologies and immune responses in BALB/c and C57BL/6 mice infected with Streptobacillus moniliformis

Juliane Fornefett, Jaqueline Krause, Kristin Klose, Felix Fingas, Rayk Hassert, Tobias Eisenberg, Wieland Schroedl, Thomas Grunwald, Uwe Mueller, Christoph G. Baums

MICROBES AND INFECTION (2018)

Article Multidisciplinary Sciences

Non-human papillomaviruses for gene delivery in vitro and in vivo

Lea Bayer, Jessica Guempel, Gerd Hause, Martin Mueller, Thomas Grunwald

PLOS ONE (2018)

Article Biochemical Research Methods

Highly sensitive ELISA for the serological detection of murine rotavirus EDIM based on its major immunogen VP6

Felix Fingas, Antje Rueckner, Kristin Heenemann, Daniela Volke, Michael Sieg, Petra Bielefeldt, Thomas Grunwald, Thomas W. Vahlenkamp, Rayk Hassert, Ralf Hoffmann

JOURNAL OF VIROLOGICAL METHODS (2018)

Article Immunology

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization

Sarah Wilmschen, Sabrina Schneider, Felix Peters, Lea Bayer, Leila Issmail, Zoltan Banki, Thomas Grunwald, Dorothee von Laer, Janine Kimpel

VACCINES (2019)

Article Multidisciplinary Sciences

Automated application of low energy electron irradiation enables inactivation of pathogen- and cell-containing liquids in biomedical research and production facilities

Jasmin Fertey, Martin Thoma, Jana Beckmann, Lea Bayer, Julia Finkensieper, Susann Reisshauer, Beatrice Sarah Berneck, Leila Issmail, Jessy Schoenfelder, Javier Portillo Casado, Andre Poremba, Frank-Holm Roegner, Bastian Standfest, Gustavo R. Makert, Lia Walcher, Ann-Kathrin Kistenmacher, Stephan Fricke, Thomas Grunwald, Sebastian Ulbert

SCIENTIFIC REPORTS (2020)

Article Immunology

A Recombinant Zika Virus Envelope Protein with Mutations in the Conserved Fusion Loop Leads to Reduced Antibody Cross-Reactivity upon Vaccination

Beatrice Sarah Berneck, Alexandra Rockstroh, Jasmin Fertey, Thomas Grunwald, Sebastian Ulbert

VACCINES (2020)

Article Immunology

A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model

Antonia Sophia Peter, Edith Roth, Sebastian R. Schulz, Kirsten Fraedrich, Tobit Steinmetz, Dominik Damm, Manuela Hauke, Elie Richel, Sandra Mueller-Schmucker, Katharina Habenicht, Valentina Eberlein, Leila Issmail, Nadja Uhlig, Simon Dolles, Eva Gruner, David Peterhoff, Sandra Ciesek, Markus Hoffmann, Stefan Pohlmann, Paul F. McKay, Robin J. Shattock, Roman Wolfel, Eileen Socher, Ralf Wagner, Jutta Eichler, Heinrich Sticht, Wolfgang Schuh, Frank Neipel, Armin Ensser, Dirk Mielenz, Matthias Tenbusch, Thomas H. Winkler, Thomas Grunwald, Klaus Uberla, Hans-Martin Jack

Summary: TRIANNI mice were used to generate 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein, and identified two clusters of neutralizing antibodies targeting different regions of the spike protein. These neutralizing antibodies significantly reduced viral spread and protected mice from SARS-CoV-2-induced weight loss, showing potential for therapy and prophylaxis of COVID-19.

EUROPEAN JOURNAL OF IMMUNOLOGY (2022)

Article Cell Biology

A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections

Christian Gege, Fernando J. Bravo, Nadja Uhlig, Timo Hagmaier, Rosanne Schmachtenberg, Julia Elis, Anke Burger-Kentischer, Doris Finkelmeier, Klaus Hamprecht, Thomas Grunwald, David Bernstein, Gerald Kleymann

Summary: The text discusses the high prevalence of chronic herpesvirus infections and introduces a new HSV helicase-primase inhibitor, IM-250, with potential in vitro anti-herpes activity. IM-250 shows advantages over standard-of-care therapies in reducing disease duration, preventing recurrence, and maintaining effectiveness post-treatment cessation.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Article Pharmacology & Pharmacy

Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model

Nadja Uhlig, Anne-Kathrin Donner, Christian Gege, Franziska Lange, Gerald Kleymann, Thomas Grunwald

Summary: The novel HPI compounds showed superior antiviral efficacy compared to the current standard HSV treatment represented by VACV in terms of survival rates, clinical scores, and reductions in viral load in the lungs and brains. These new drug candidates are promising for the treatment of HSV infections and warrant further translation into clinical trials.

ANTIVIRAL RESEARCH (2021)

Article Multidisciplinary Sciences

Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

Dennis Lapuente, Jana Fuchs, Jonas Willar, Ana Vieira Antao, Valentina Eberlein, Nadja Uhlig, Leila Issmail, Anna Schmidt, Friederike Oltmanns, Antonia Sophia Peter, Sandra Mueller-Schmucker, Pascal Irrgang, Kirsten Fraedrich, Andrea Cara, Markus Hoffmann, Stefan Poehlmann, Armin Ensser, Cordula Pertl, Torsten Willert, Christian Thirion, Thomas Grunwald, Klaus Ueberla, Matthias Tenbusch

Summary: The study demonstrates that priming with systemic mRNA and boosting with intranasal adenoviral vector vaccine in mice induces comprehensive T cell and mucosal immunity. The strategy provides complete protection against SARS-CoV-2 infection in mice after boosting.

NATURE COMMUNICATIONS (2021)

Article Chemistry, Multidisciplinary

Macromolecular Viral Entry Inhibitors as Broad-Spectrum First-Line Antivirals with Activity against SARS-CoV-2

Rudiger Gross, Livia Mesquita Dias Loiola, Leila Issmail, Nadja Uhlig, Valentina Eberlein, Carina Conzelmann, Lia-Raluca Olari, Lena Rauch, Jan Lawrenz, Tatjana Weil, Janis A. Mueller, Mateus Borba Cardoso, Andrea Gilg, Olivia Larsson, Urban Hoeglund, Sandra Axberg Palsson, Anna Selch Tvilum, Kaja Borup Lovschall, Maria M. Kristensen, Anna-Lena Spetz, Fortune Hontonnou, Marie Galloux, Thomas Grunwald, Alexander N. Zelikin, Jan Munch

Summary: This study investigates the use of poly(styrene sulfonate)-based inhibitors and core-shell nanoformulations based on gold nanoparticles against a range of viruses, including SARS-CoV-2. The macromolecular inhibitors show broad-spectrum antiviral activity and effectively inhibit enveloped respiratory viruses. The findings provide valuable insights into the development of antiviral drugs.

ADVANCED SCIENCE (2022)

Article Immunology

Low-Energy Electron Irradiation of Tick-Borne Encephalitis Virus Provides a Protective Inactivated Vaccine

Julia Finkensieper, Leila Issmail, Jasmin Fertey, Alexandra Rockstroh, Simone Schopf, Bastian Standfest, Martin Thoma, Thomas Grunwald, Sebastian Ulbert

Summary: Tick-borne encephalitis virus (TBEV) is a zoonotic flavivirus that can cause severe neurological complications in humans. Traditional methods of producing TBEV vaccines using formaldehyde have drawbacks, and this study suggests that low-energy electron irradiation (LEEI) could be an alternative method. Immunizing mice with LEEI-inactivated TBEV resulted in higher levels of antibodies and complete protection against viral challenge.

FRONTIERS IN IMMUNOLOGY (2022)

Article Multidisciplinary Sciences

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication

Kim M. Stegmann, Antje Dickmanns, Natalie Heinen, Claudia Blaurock, Tim Karrasch, Angele Breithaupt, Robert Klopfleisch, Nadja Uhlig, Valentina Eberlein, Leila Issmail, Simon T. Herrmann, Amelie Schreieck, Evelyn Peelen, Hella Kohlhof, Balal Sadeghi, Alexander Riek, John R. Speakman, Uwe Gross, Dirk Gorlich, Daniel Vitt, Thorsten Muller, Thomas Grunwald, Stephanie Pfaender, Anne Balkema-Buschmann, Matthias Dobbelstein

Summary: This study demonstrates a strong synergy between the nucleoside analog N4-hydroxycytidine (NHC) and inhibitors of dihydroorotate dehydrogenase (DHODH) in inhibiting the replication of SARS-CoV-2. Inhibition of DHODH increases the incorporation of NHC into viral RNA, leading to defective virus genomes. The combination of NHC and DHODH inhibitors may improve therapy options for COVID-19.

ISCIENCE (2022)

Article Chemistry, Multidisciplinary

Advanced Molecular Tweezers with Lipid Anchors against SARS-CoV-2 and Other Respiratory Viruses

Tatjana Weil, Abbna Kirupakaran, My-Hue Le, Philipp Rebmann, Joel Mieres-Perez, Leila Issmail, Carina Conzelmann, Janis A. Mueller, Lena Rauch, Andrea Gilg, Lukas Wettstein, Ruediger Gross, Clarissa Read, Tim Bergner, Sandra Axberg Palsson, Nadja Uhlig, Valentina Eberlein, Heike Woell, Frank-Gerrit Klaerner, Steffen Stenger, Beate M. Kuemmerer, Hendrik Streeck, Giorgio Fois, Manfred Frick, Peter Braubach, Anna-Lena Spetz, Thomas Grunwald, James Shorter, Elsa Sanchez-Garcia, Thomas Schrader, Jan Muench

Summary: This study discovered that a class of drugs called molecular tweezers can disrupt the envelope of SARS-CoV-2 and render the virus non-infectious. By modifying the molecular structure, researchers identified a series of advanced molecular tweezers that showed enhanced ability to destroy lipid bilayers and suppress SARS-CoV-2 infection. These potentiated tweezers demonstrated activity against various viruses, including respiratory syncytial virus, influenza, and measles viruses, in addition to SARS-CoV-2. The inhibitory effects of the advanced tweezers against respiratory syncytial virus and SARS-CoV-2 were also validated in mice. Therefore, these broad-spectrum antiviral agents have great potential for clinical development in combating highly pathogenic viruses.

JACS AU (2022)

No Data Available